Conditions: Carcinoma, Non-Small-Cell Lung (NSCLC)
Keywords: AG-013736 axitinib cisplatin gemcitabine NSCLC squamous cell lung cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 38
Healthy volunteers: no

Brief summary:
This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: AG-013736 intervention 2: gemcitabine intervention 3: cisplatin
Intervention descriptions: intervention 1: AG-013736 5 mg tablets orally, twice daily, until disease progression intervention 2: 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles intervention 3: 1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles

Protocol document: